GO
Loading...

Squawk Box

More

  • Yummie: Not your grandma's girdle anymore     Wednesday, 23 Apr 2014 | 6:50 AM ET

    It's not a dirty little secret anymore, says Heather Thomson, Yummie by Heather Thomson founder, discussing how her company is redefining the shapewear industry and carving out a piece of the market.

  • Don't look at tech as one big blob: Pro     Wednesday, 23 Apr 2014 | 6:33 AM ET

    Investors need to separate new tech from old tech, says Christopher Wolfe, Merrill Lynch, sharing his views on whether there's a tech bubble brewing. And Mark Haefele, UBS Wealth Management, weighs in.

  • iPhone 6 will reward Apple: Analyst     Wednesday, 23 Apr 2014 | 6:13 AM ET

    Chris Caso, Susquehanna Financial Group analyst, shares his outlook on Apple in the second half. Apple needs to show shareholders the next new thing, says Caso.

  • Pharma deal frenzy     Tuesday, 22 Apr 2014 | 10:01 AM ET

    CNBC's Meg Tirrell digs into the friendly and hostile M&A action taking place in pharmaceuticals, including a deal between Novartis and GlaxoSmithKline, and Valeant Pharmaceuticals bid for Allergan.

  • Don't start your trading day without finding out what CNBC's Jim Cramer is watching ahead of the opening bell.

  • USDA: Chances of El Nino now 50-67%     Tuesday, 22 Apr 2014 | 8:42 AM ET

    CNBC's Jane Wells reports on the good and bad of El Nino if it develops near South American mines, and coffee and cocoa.

  • McDonald's 'not broken story': Analyst     Tuesday, 22 Apr 2014 | 8:33 AM ET

    McDonald's reported Q1 EPS of $1.21 on revenue of $6.7 billion. RJ Hottovy of Morningstar, still sees value in the stock.

  • Citi shareholders to vote on exec compensation     Tuesday, 22 Apr 2014 | 8:14 AM ET

    Citi investors are in St. Louis today for the bank's annual shareholder meeting. CNBC's Kayla Tausche provides insight into the day's schedule.

  • Valeant's offer for Allergan     Tuesday, 22 Apr 2014 | 8:03 AM ET

    Valeant Pharmaceuticals offered $48.30 share cash, as well as 0.83 shares for Allergan. CNBC's Meg Tirrell provides insight.

  • Why cancer drug newcomer GSK is getting out: CEO Tuesday, 22 Apr 2014 | 8:06 AM ET

    The megabillion-dollar deals with Novartis also allow GlaxoSmithKline to "significantly expand" its world-leading vaccine business, GSK's CEO tells CNBC.

  • McDonald's reports Q1 earnings     Tuesday, 22 Apr 2014 | 7:58 AM ET

    McDonald's is reporting Q1 EPS of $1.21 on revenue of $6.700 billion, with the "Squawk Box" crew.

  • Morning stock picks     Tuesday, 22 Apr 2014 | 7:47 AM ET

    Chris Baggini of Turner Titan Fund, explains his top three stock picks for investors right now. He says Facebook's advertising model is "very strong."

  • Reality for Netflix     Tuesday, 22 Apr 2014 | 7:41 AM ET

    BTIG media and tech analyst Rich Greenfield, questions why some of the bandwidth burden should or shouldn't fall on Netflix.

  • Keep buying Time Warner Cable: Analyst     Tuesday, 22 Apr 2014 | 7:38 AM ET

    Comcast reported $0.68 ex-items on revenue of $17.408 billion in Q1. BTIG media and tech analyst Rich Greenfield, discusses cable network advertising, and explains the opportunities that could arise from the Time Warner Cable and Comcast deal.

  • Eli Lilly Chairman & CEO John Lechleiter discusses his business' expansion of its animal health unit with the acquisition of Novartis' animal health business.

  • What the market's signaling     Tuesday, 22 Apr 2014 | 7:10 AM ET

    Discussing current market conditions, and how the activist investor is changing the conversation in the board room, with Julian Emanuel, UBS, and Charles Kantor, Neuberger Berman.

  • Comcast reports Q1 earnings     Tuesday, 22 Apr 2014 | 7:00 AM ET

    Comcast is reporting $0.68 ex-items on revenue of $17.408 billion, with the "Squawk Box" crew.

  • Novartis acquisition adds 'tremendous value'     Tuesday, 22 Apr 2014 | 6:45 AM ET

    GlaxoSmithKline CEO Sir Andrew Witty, discusses the benefit to shareholders from his company's acquisition of Novartis' vaccination business, as well as its oncology unit.

  • GlaxoSmithKline CEO Sir Andrew Witty, explains the large portfolio of vaccinations his company provides, and the value added from the company's acquisition of Novartis' vaccination business.

  • Correction over, buy the market: Pro     Tuesday, 22 Apr 2014 | 6:34 AM ET

    Dissecting current market action, and the building M&A cycle, with Mary Ann Bartels, Merrill Lynch Wealth Management. "We think capex will be the next step for investing," she explains.

About Squawk Box

  • "Squawk Box" is the ultimate "pre-market" morning news and talk program, where the biggest names in business and politics tell their most important stories. Anchored by Joe Kernen, Becky Quick and Andrew Ross Sorkin, the show brings Wall Street to Main Street. It's a "must see" for everyone from the professional trader to the casual investor.

Contact Squawk Box

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    › Learn More
  • Showtimes

    U.S.
    Weekdays 6a ET
    EMEA
    Weekdays 13:00 CET
    Asia
    Weekdays 18:00 SIN/HK
    Australia
    Weekdays 20:00 SYD
    New Zealand
    Weekdays 22:00 NZ

 

  • Joe Kernen is co-anchor of "Squawk Box," CNBC's signature morning program.

  • "Squawk Box" Co-Anchor

  • Andrew Ross Sorkin is a co-anchor of "Squawk Box," a financial columnist for "The New York Times" and the editor-at-large of NYT's DealBook.